Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
Bevacizumab is the only therapeutic target approved for patients with persistent, recurrent or advanced cervical cancer from a phase III study that combined with chemotherapy; it proves a significant increase in overall survival.
Nerve Sparing Approach Improves Outcomes of Patients Undergoing Minimally Invasive Radical Hysterectomy: a Systematic Review and Meta-Analysis.
Few studies investigated the efficacy and safety of nerve sparing approach via minimally invasive surgery for the treatment of cervical cancer. We aimed to review the current evidence comparing nerve sparing minimally invasive...
Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study.
Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning.
Introduction: Cervical cancer is still a major cause of morbidity and mortality in women. Early stages and locally advanced cervical...
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
BACKGROUND: Despite preventive vaccines for oncogenic human papillomaviruses (HPVs), cervical intraepithelial neoplasia (CIN) is common, and current treatments are ablative...
Cancer constitutes an enormous burden on society in more and less economically developed countries alike.